Literature DB >> 8945593

Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G.

A Norrby-Teglund1, R Kaul, D E Low, A McGeer, J Andersson, U Andersson, M Kotb.   

Abstract

Recently we demonstrated that normal polyspecific immunoglobulin given intravenously (IVIG) and plasma samples from patients treated with IVIG neutralize the mitogenic and cytokine-inducing activities of group A streptococcal (GAS) superantigens. Here we investigated whether this neutralizing activity is mediated by antibodies to these superantigens. IVIG and plasma samples collected from a patient with GAS necrotizing fasciitis post-IVIG infusions markedly inhibited the mitogenic activity elicited by the streptococcal pyrogenic exotoxins SpeB and SpeC, as well as by GAS culture supernatant. Immunoblot analysis showed marked increases in the levels of antibodies to SpeC and proteins in the GAS culture supernatant in post-IVIG over those of pre-IVIG plasma samples. Removal of antisuperantigen antibodies in IVIG by adsorption to SpeC- and GAS culture supernatant-coupled Sepharose markedly reduced the neutralizing ability of IVIG against respective stimuli. The neutralizing activity was totally recovered in the eluted antibodies. By contrast, although pre- and post-IVIG plasma samples contained antibodies to SpeA, these antibodies did not block the activity of this superantigen. Nonspecific immunomodulatory activity of IVIG was ruled out because neither the IVIG nor the affinity-purified antibodies significantly inhibited the response to the polyclonal T-cell mitogen phytohemagglutinin A. These data provide direct evidence that the neutralizing activity in IVIG, and in patient plasma samples following IVIG treatment is mediated by antibodies to superantigens and indicate that the quality rather than the quantity of these antibodies may be more clinically relevant.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945593      PMCID: PMC174535          DOI: 10.1128/iai.64.12.5395-5398.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

Review 1.  Invasive group A streptococcus infections.

Authors:  D L Stevens
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

Review 2.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

3.  Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project.

Authors:  R Watanabe-Ohnishi; D E Low; A McGeer; D L Stevens; P M Schlievert; D Newton; B Schwartz; B Kreiswirth; M Kotb
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

4.  Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment].

Authors:  S Takei; Y K Arora; S M Walker
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 5.  Role of superantigens in human disease.

Authors:  P M Schlievert
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

6.  T cell activation and cytokine release in streptococcal toxic shock-like syndrome.

Authors:  D Nadal; R P Lauener; C P Braegger; A Kaufhold; B Simma; R Lütticken; R A Seger
Journal:  J Pediatr       Date:  1993-05       Impact factor: 4.406

Review 7.  The staphylococcal enterotoxins and their relatives.

Authors:  P Marrack; J Kappler
Journal:  Science       Date:  1990-05-11       Impact factor: 47.728

8.  Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).

Authors:  A Norrby-Teglund; D Newton; M Kotb; S E Holm; M Norgren
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.

Authors:  A Norrby-Teglund; R Kaul; D E Low; A McGeer; D W Newton; J Andersson; U Andersson; M Kotb
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

10.  Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease.

Authors:  A Norrby-Teglund; K Pauksens; S E Holm; M Norgren
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

View more
  24 in total

1.  Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Molecular diagnosis of necrotizing fasciitis by 16S rRNA gene sequencing and superantigen gene detection.

Authors:  Kenneth L Muldrew; Jean F Simpson; Charles W Stratton; Yi-Wei Tang
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

3.  IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection.

Authors:  Per Akesson; Linnea Moritz; Mikael Truedsson; Bertil Christensson; Ulrich von Pawel-Rammingen
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

5.  Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.

Authors:  H Basma; A Norrby-Teglund; A McGeer; D E Low; O El-Ahmedy; J B Dale; B Schwartz; M Kotb
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity.

Authors:  H Basma; A Norrby-Teglund; Y Guedez; A McGeer; D E Low; O El-Ahmedy; B Schwartz; M Kotb
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

7.  Inactivation of Streptococcus pyogenes extracellular cysteine protease significantly decreases mouse lethality of serotype M3 and M49 strains.

Authors:  S Lukomski; S Sreevatsan; C Amberg; W Reichardt; M Woischnik; A Podbielski; J M Musser
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

8.  [60 year old patient with soft tissue infection of the right leg].

Authors:  D Hasper; D Schrage; K-D Schaser; I Melcher; D Barckow; U Frei; M Oppert
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

Review 9.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

10.  Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.

Authors:  N Farag; L Mahran; K Abou-Aisha; M El-Azizi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.